Subscribe To
There is no positive catalyst that can revive draftkings now
As DraftKings' outlays far exceed the company's revenues, it's only getting harder to hold fast-declining DKNG stock with confidence. The post There I...
January 24, 2022, 10:37 am
There is no positive catalyst that can revive draftkings now
As DraftKings' outlays far exceed the company's revenues, it's only getting harder to hold fast-declining DKNG stock with confidence. The post There I...
January 24, 2022, 10:37 am
Investing in draftkings stock looks like a winning bet in 2022
DraftKings, the leading sports gaming platform has recently lost more than half of its value. Now, DKNG stock offers better value....
January 21, 2022, 4:24 pm
Investing in draftkings stock looks like a winning bet in 2022
DraftKings, the leading sports gaming platform has recently lost more than half of its value. Now, DKNG stock offers better value....
January 21, 2022, 4:24 pm
Investing in draftkings stock looks like a winning bet in 2022
DraftKings, the leading sports gaming platform has recently lost more than half of its value. Now, DKNG stock offers better value....
January 21, 2022, 4:24 pm
Is draftkings stock a buy or sell with new york sports gambling approval?
DraftKings stock's premium valuation has been digested by the market, as it trades near its peers' valuations....
January 21, 2022, 1:54 pm
Is draftkings stock a buy or sell with new york sports gambling approval?
DraftKings stock's premium valuation has been digested by the market, as it trades near its peers' valuations....
January 21, 2022, 1:54 pm
Is draftkings stock a buy or sell with new york sports gambling approval?
DraftKings stock's premium valuation has been digested by the market, as it trades near its peers' valuations....
January 21, 2022, 1:54 pm
Metals stocks: gold retreats, set for back-to-back drop, but on track for sharpest weekly gain since november
Gold futures were trading lower Friday morning, headed for a second straight decline, but that belies the weekly up...
January 21, 2022, 8:39 am
Metals stocks: gold retreats, set for back-to-back drop, but on track for sharpest weekly gain since november
Gold futures were trading lower Friday morning, headed for a second straight decline, but that belies the weekly up...
January 21, 2022, 8:39 am
Metals stocks: gold retreats, set for back-to-back drop, but on track for sharpest weekly gain since november
Gold futures were trading lower Friday morning, headed for a second straight decline, but that belies the weekly up...
January 21, 2022, 8:39 am
Roku stock was all over the board today -- is it a buy?
The market downdraft has taken the wind out of Roku's sails. Is it time for investors to pounce?...
January 20, 2022, 6:23 pm
Roku stock was all over the board today -- is it a buy?
The market downdraft has taken the wind out of Roku's sails. Is it time for investors to pounce?...
January 20, 2022, 6:23 pm
Roku stock was all over the board today -- is it a buy?
The market downdraft has taken the wind out of Roku's sails. Is it time for investors to pounce?...
January 20, 2022, 6:23 pm
Bank of america slashes its overdraft fees
Amid increased scrutiny from the CFPB towards banks' overdraft fees, Bank of America announced it is re...
January 20, 2022, 12:27 pm
Bank of america slashes its overdraft fees
Amid increased scrutiny from the CFPB towards banks' overdraft fees, Bank of America announced it is re...
January 20, 2022, 12:27 pm
Bank of america slashes its overdraft fees
Amid increased scrutiny from the CFPB towards banks' overdraft fees, Bank of America announced it is re...
January 20, 2022, 12:27 pm
Omeros submits response to fda regarding narsoplimab application in hsct-tma
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transp...
January 20, 2022, 6:54 am
Omeros submits response to fda regarding narsoplimab application in hsct-tma
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transp...
January 20, 2022, 6:54 am
Omeros submits response to fda regarding narsoplimab application in hsct-tma
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transp...
January 20, 2022, 6:54 am